within Pharmacolibrary.Drugs.ATC.C;

model C07FX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 0.001,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.2,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.02,
    Tlag           = 600,            
    Vdp             = 0.05,
    k12             = 30,
    k21             = 30
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C07FX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Fixed combination of metoprolol (a selective beta-1 adrenergic blocker used for hypertension, angina, and heart failure) and acetylsalicylic acid (aspirin, an antiplatelet and anti-inflammatory agent for cardiovascular prevention). Intended to reduce blood pressure and risk of cardiovascular complications, generally for secondary prevention post-myocardial infarction or for cardiovascular risk reduction. This fixed-dose combination is approved in certain regions but not globally available as of 2024.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from individual component data (metoprolol tartrate and acetylsalicylic acid) in healthy adults, as no published study reports PK parameters for the fixed combination product.</p><h4>References</h4><ol><li><p>Miners, JO (1989). Drug interactions involving aspirin (acetylsalicylic acid) and salicylic acid. <i>Clinical pharmacokinetics</i> 17(5) 327–344. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198917050-00003&quot;>10.2165/00003088-198917050-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2573442/&quot;>https://pubmed.ncbi.nlm.nih.gov/2573442</a></p></li><li><p>Melander, A, &amp; McLean, A (1983). Influence of food intake on presystemic clearance of drugs. <i>Clinical pharmacokinetics</i> 8(4) 286–296. DOI:<a href=&quot;https://doi.org/10.2165/00003088-198308040-00002&quot;>10.2165/00003088-198308040-00002</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6352137/&quot;>https://pubmed.ncbi.nlm.nih.gov/6352137</a></p></li><li><p>Koya, Y, et al., &amp; Kotegawa, T (2016). Prediction of drug interaction between oral adsorbent AST-120 and concomitant drugs based on the in vitro dissolution and in vivo absorption behavior of the drugs. <i>European journal of clinical pharmacology</i> 72(11) 1353–1361. DOI:<a href=&quot;https://doi.org/10.1007/s00228-016-2102-5&quot;>10.1007/s00228-016-2102-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27491774/&quot;>https://pubmed.ncbi.nlm.nih.gov/27491774</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C07FX03;
